Navigation Links
Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Date:10/22/2008

ase visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, timing and results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and its Quarterly Report on Form 10-Q for the period ended June 30, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuti
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...peak at Economic Club of Canada , ... -- Ambassador to Speak at Economic Club of Canada...r International Investment, and Chairman and CEO o... of David Appia go to www.investinfrance.org . ,...ith press to discuss recent pro-business initiativ...
(Date:11/25/2009)...PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a...nced today that it executed,a joint venture (JV) a...hnology Co., Ltd. (Sinovac Dalian). The JV will re...se vaccines. Sinovac will contribute its expertise...world-class vaccines; the,other party will bring i...
(Date:11/24/2009)... , Whether it,s CD packaging, containers or ...dentification) are increasingly finding their way ... objects or goods and identify them automatically ...ad and process the data contained in the label. Sm...n conditions of up to 100 degrees Celsius. But at ...
(Date:11/24/2009)...vestment bank KTA Capital,s client Neuren Pharmace...vertible note private placement with a U.S. instit...ed by KTA Capital as Neuren,s exclusive placement ...York (PRWEB) November 23, 2009 -- The independent ...TA Capital") has announced that its client Ne...
Breaking Biology Technology:French Ambassador for International Investment to Visit Toronto December 11 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
... and WHITEHOUSE STATION, N.J., April 25 ,Schering-... that it,received a not-approvable letter from the...posed fixed combination of loratadine and monteluk...s in patients who want relief,from nasal congestio...e/montelukast was accepted,by the FDA for standard...
...FRANCISCO, Calif., April 25 ,Renovis, Inc. (Nasdaq...Inc.,and Egan-Jones Proxy Services have joined ISS...g that Renovis stockholders vote "FOR" the merger,...: EVT) at the Special,Meeting of Stockholders sche... share of Renovis common stock will be converted i...
...NTY, Calif., April 25 Beckman,Coulter, Inc. (NYSE...rs,declared a quarterly dividend payout of sevente...tock, payable on May 23, 2008 to all stockholders ...he 76th consecutive,quarterly payout of dividends....31202/BECLOGO ), Beckman Coulter, Inc., based in ...
Other Biology Technology:Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 2Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 3Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec 2Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec 3
(Date:11/26/2009)...(November 26, 2009) Whitehead researchers have de...ls to pinpoint specific genes and proteins used by... , In most human cell cultures genes are present...one from the mother. Gene inactivation by mutation... inactivated, the second copy usually remains acti...
(Date:11/25/2009)...eria don,t have easy lives. In addition to mammali... natural enemies called bacteriophages, viruses th... , Still, bacteria and another class of microor...e environments such as deep-sea volcanic vents) ma...ve a built-in defense system that helps protect th...
(Date:11/25/2009)...iversity assistant professors recently received fu...o continue research beneficial to understanding th... Christopher Blackwood, assistant professor in th...rants to support two separate research projects. ,...composer Communities and Functions from the Leaf t...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Kent State University professors focus research on the environment with grants totaling $890,000 2Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference 13733 1Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference 13733 2Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference 13733 3Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference 13733 4Researchers identify protein involved in causing gum disease osteoporosis arthritis 55657 1Researchers identify protein involved in causing gum disease osteoporosis arthritis 55657 2Researchers identify protein involved in causing gum disease osteoporosis arthritis 55657 3Young Athletes at Risk of Heat Injury 55656 1Young Athletes at Risk of Heat Injury 55656 2
... basic components of living things, are among the ...ing how proteins form or "fold" from sequenced str... challenges of biology. , A common belief holds t...nment, the more stable - or less likely to unfold ...e March issue of Biophysical Journal, a team of ch...
...velop their preference for speech through in-utero...nate? It,s a bedevilling question to test, but one...ynamics of humans unique propensity for speech. No...separated out the complicating effects of the uter...a Vouloumanos, point to a genetic predilection for...
...sts and engineers at the University of Toronto des...ould help satisfy society,s never-ending hunger fo...d even lead to new methods for delivering medicati...iodic mesoporous organosilica (PMO), is a thin fil... metre across. The team created it by mixing an or...
Other Biology News:UW-Madison engineers squeeze secrets from proteins 2Born with a love of speech 2Born with a love of speech 3
...0 (CYP450) metabolite postulated to play an autaco...rat cerebral microvessels, 20-HETE is a vasoconstr...y vasoconstriction. 20-HETE is excreted mainly as ...ee 20-HETE (20-40 pg/ml in human urine) is about 1...
...m enables you to insert a transposable element of ... transposition. It uses TnsABC* Transposase to ins... target. Target DNA may be a plasmid, cosmid, BAC ...nterests (6-8). If the insertion site is within a ...
Peptide Standards from New England Biolabs
CORNING CELLSTACK VENTED CAP, 33MM, STERILE, 0.2UM MEMBRANE from Sigma-Aldrich
Biology Products: